Relevant bibliographies by topics / Treatment targets / Journal articles

Journal articles on the topic 'Treatment targets'

To see the other types of publications on this topic, follow the link: Treatment targets.
Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Treatment targets.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Davies, Nick, Tim Peakman, and Steve Arlington. "From targets to targeted treatment solutions." Drug Discovery Today 9, no. 6 (March 2004): 245–47. http://dx.doi.org/10.1016/s1359-6446(03)02915-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Simon, Richard. "Targets for treatment success." Nature Clinical Practice Oncology 3, no. 1 (January 2006): 1. http://dx.doi.org/10.1038/ncponc0402.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bradbury, Jane. "Potential atherosclerosis treatment targets?" Lancet 353, no. 9161 (April 1999): 1334. http://dx.doi.org/10.1016/s0140-6736(05)74331-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lipworth, B. J. "Targets for inhaled treatment." Respiratory Medicine 94 (September 2000): S13—S16. http://dx.doi.org/10.1016/s0954-6111(00)80135-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

LIPWORTH, B. "Targets for inhaled treatment." Respiratory Medicine 94 (September 2000): S13—S16. http://dx.doi.org/10.1016/s0954-6111(00)90118-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Goadsby, PeterJames, David Moreno-Ajona, and MaríaDolores Villar-Martínez. "Emerging Targets for Migraine Treatment." Neurology India 69, no. 7 (2021): 98. http://dx.doi.org/10.4103/0028-3886.315989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Field, Benjamin C. T., Owais B. Chaudhri, and Stephen R. Bloom. "Obesity treatment: novel peripheral targets." British Journal of Clinical Pharmacology 68, no. 6 (December 2009): 830–43. http://dx.doi.org/10.1111/j.1365-2125.2009.03522.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Otto, Grant. "Novel targets for itch treatment." Nature Reviews Drug Discovery 18, no. 9 (July 19, 2019): 666. http://dx.doi.org/10.1038/d41573-019-00126-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Khanna, Reena, and Vipul Jairath. "Treatment Targets in Ulcerative Colitis." Gastroenterology 151, no. 5 (November 2016): 1030–32. http://dx.doi.org/10.1053/j.gastro.2016.09.028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lillegraven, Siri, and Espen A. Haavardsholm. "Subclinical Treatment Targets in Rheumatology." Rheumatic Disease Clinics of North America 45, no. 4 (November 2019): 593–604. http://dx.doi.org/10.1016/j.rdc.2019.07.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Paterlini, Marta. "Combined treatment targets chemorefractory tumours." Lancet Oncology 9, no. 1 (January 2008): 16. http://dx.doi.org/10.1016/s1470-2045(07)70402-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

MOON, MARY ANN. "Guideline Targets NAFLD Diagnosis, Treatment." Internal Medicine News 45, no. 10 (June 2012): 14. http://dx.doi.org/10.1016/s1097-8690(12)70430-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Carvalhão Gil, L., M. Lázaro, A. Ponte, J. Teixeira, H. Prata Ribeiro, and T. Mota. "Treatment of alcoholism – New targets?" European Psychiatry 41, S1 (April 2017): s859. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1713.

Full text
Abstract:
IntroductionAlcohol use disorders (AUD) is a preventable cause of significant morbidity and mortality worldwide. AUD is a heterogeneous disorder stemming from a complex interaction of neurobiological, genetic, and environmental factors. To achieve treatment effectiveness this heterogenity should be considered, as well as safety.ObjectivesReview mechanisms underlying alcohol addiction in order to work out new, more effective treatment strategies.AimTo update on treatment for alcoholism.MethodsA literature search was performed on PubMed database.ResultsAlcohol dependence is a chronic, relapsing condition in which there is evidence of significant change in the motivation and control systems in the brain. Increasingly drug therapy is focused not just on the treatment of the acute withdrawal syndrome, but on modifying these other dysregulated brain systems. Of the numerous neurotransmitter systems that have been identified for the development of new medicines, the most promising compounds appear to be those that modulate the function of opioids, glutamate with or without gamma-aminobutyric acid, and serotonin. Other putative therapeutic medications including direct modulators of dopamine function and enzyme inhibitors also shall be discussed. At present, only four medications are approved for the treatment of alcohol dependence in Europe, that is naltrexone, acamprosate, disulfiram and the most recent nalmefene. Among other promising strategies the following drugs are mentioned: baclofen, topiramate, ondansetron, aripiprazole, rimonabant and varenicline.ConclusionsPharmacological development remains a high priority in the alcoholism field. Drugs have different safety profiles that need to be balanced with the treatment objective, individual patient preferences and comorbid conditions.Disclosure of interestThe authors have not supplied their declaration of competing interest.
APA, Harvard, Vancouver, ISO, and other styles
14

Sangha, Navdeep, and Nicole R. Gonzales. "Treatment Targets in Intracerebral Hemorrhage." Neurotherapeutics 8, no. 3 (July 2011): 374–87. http://dx.doi.org/10.1007/s13311-011-0055-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Roux, Sophie. "New treatment targets in osteoporosis." Joint Bone Spine 77, no. 3 (May 2010): 222–28. http://dx.doi.org/10.1016/j.jbspin.2010.02.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Boor, P., K. Sebekova, T. Ostendorf, and J. Floege. "Treatment targets in renal fibrosis." Nephrology Dialysis Transplantation 22, no. 12 (August 25, 2007): 3391–407. http://dx.doi.org/10.1093/ndt/gfm393.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Thaker, Gunvant K. "Schizophrenia endophenotypes as treatment targets." Expert Opinion on Therapeutic Targets 11, no. 9 (September 2007): 1189–206. http://dx.doi.org/10.1517/14728222.11.9.1189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Johnson, P. W. M. "New targets for lymphoma treatment." Annals of Oncology 19 (June 2008): iv56—iv59. http://dx.doi.org/10.1093/annonc/mdn198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Catapano, Alberico L. "Atherogenic lipoproteins as treatment targets." Nature Reviews Cardiology 15, no. 2 (January 16, 2018): 75–76. http://dx.doi.org/10.1038/nrcardio.2017.221.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Kim, Michael H. "Treatment Targets in Atrial Fibrillation." Journal of the American College of Cardiology 61, no. 4 (January 2013): 461–62. http://dx.doi.org/10.1016/j.jacc.2012.08.1027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Heath, Victoria, and Roy Bicknell. "New targets in cancer treatment." Drug Discovery Today: Therapeutic Strategies 4, no. 4 (December 2007): 209–10. http://dx.doi.org/10.1016/j.ddstr.2008.04.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Friedrich, Debra A., Dean G. Karalis, Karen E. Aspry, Seth S. Martin, and John R. Guyton. "JCL roundtable: Lipid treatment targets." Journal of Clinical Lipidology 13, no. 2 (March 2019): 223–30. http://dx.doi.org/10.1016/j.jacl.2019.04.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Storkel, Holly L. "The Complexity Approach to Phonological Treatment: How to Select Treatment Targets." Language, Speech, and Hearing Services in Schools 49, no. 3 (July 5, 2018): 463–81. http://dx.doi.org/10.1044/2017_lshss-17-0082.

Full text
Abstract:
Purpose There are a number of evidence-based treatments for preschool children with phonological disorders (Baker & McLeod, 2011). However, a recent survey by Brumbaugh and Smit (2013) suggests that speech-language pathologists are not equally familiar with all evidence-based treatment alternatives, particularly the complexity approach. The goal of this clinical tutorial is to provide coaching on the implementation of the complexity approach in clinical practice, focusing on treatment target selection. Method Evidence related to selecting targets for treatment based on characteristics of the targets (i.e., developmental norms, implicational universals) and characteristics of children's knowledge of the targets (i.e., accuracy, stimulability) is reviewed. Free resources are provided to aid clinicians in assessing accuracy and stimulability of singletons and clusters. Use of treatment target selection and generalization prediction worksheets is illustrated with 3 preschool children. Results Clinicians can integrate multiple pieces of information to select complex targets and successfully apply the complexity approach to their own clinical practice. Conclusion Incorporating the complexity approach into clinical practice will expand the range of evidence-based treatment options that clinicians can use when treating preschool children with phonological disorders. Supplemental Material S1 https://doi.org/10.23641/asha.6007562 KU ScholarWorks Supplemental Material http://hdl.handle.net/1808/24767
APA, Harvard, Vancouver, ISO, and other styles
24

Grundy, Scott M. "Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?" Current Cardiology Reports 14, no. 6 (September 6, 2012): 692–700. http://dx.doi.org/10.1007/s11886-012-0305-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Goadsby, Peter J. "New targets in acute migraine treatment." Future Neurology 1, no. 2 (March 2006): 171–77. http://dx.doi.org/10.2217/14796708.1.2.171.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Janne, P. A. "Gene Translocations as Targets for Treatment." Annals of Oncology 24 (March 2013): i7. http://dx.doi.org/10.1093/annonc/mdt042.24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Iacobucci, G. "Hospital treatment targets have been simplified." BMJ 350, jun05 12 (June 5, 2015): h3090. http://dx.doi.org/10.1136/bmj.h3090.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Burnett, Arthur L., Irwin Goldstein, Karl-Erik Andersson, Antonio Argiolas, George Christ, Kwangsung Park, and Zhong C. Xin. "Future Sexual Medicine Physiological Treatment Targets." Journal of Sexual Medicine 7, no. 10 (October 2010): 3269–304. http://dx.doi.org/10.1111/j.1743-6109.2010.02025.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

WILSON, J. W. "Vessels: new targets for asthma treatment." Thorax 56, no. 12 (December 1, 2001): 899–900. http://dx.doi.org/10.1136/thorax.56.12.899.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Sever, P. S. "Management targets and thresholds for treatment." British Medical Bulletin 50, no. 2 (1994): 460–71. http://dx.doi.org/10.1093/oxfordjournals.bmb.a072903.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Tsioufis, Costas, Costas Thomopoulos, and Reinhold Kreutz. "Treatment Thresholds and Targets in Hypertension." Hypertension 71, no. 6 (June 2018): 966–68. http://dx.doi.org/10.1161/hypertensionaha.118.10815.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Buse, John B. "Individualizing treatment targets in diabetes care." Nature Reviews Endocrinology 7, no. 2 (January 24, 2011): 67–68. http://dx.doi.org/10.1038/nrendo.2010.230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Elliott, W. J. "Treatment blood pressure targets for hypertension." Yearbook of Cardiology 2010 (January 2010): 37–39. http://dx.doi.org/10.1016/s0145-4145(09)79788-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Leonard, B. E. "C.07.01 Innovative antidepressant treatment targets." European Neuropsychopharmacology 20 (August 2010): S641—S642. http://dx.doi.org/10.1016/s0924-977x(10)70989-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

SULLIVAN, MICHELE G. "Plan Targets Alzheimer's Treatment by 2025." Internal Medicine News 45, no. 10 (June 2012): 16. http://dx.doi.org/10.1016/s1097-8690(12)70435-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Walcott, Brian P., Kristopher T. Kahle, and J. Marc Simard. "Novel Treatment Targets for Cerebral Edema." Neurotherapeutics 9, no. 1 (November 29, 2011): 65–72. http://dx.doi.org/10.1007/s13311-011-0087-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Chen, Minglei, Hongzhi Qiao, Zhigui Su, Huipeng Li, Qineng Ping, and Li Zong. "Emerging therapeutic targets for osteoporosis treatment." Expert Opinion on Therapeutic Targets 18, no. 7 (April 25, 2014): 817–31. http://dx.doi.org/10.1517/14728222.2014.912632.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Ibrahim, Hisham M., and Carol A. Tamminga. "Schizophrenia: Treatment Targets Beyond Monoamine Systems." Annual Review of Pharmacology and Toxicology 51, no. 1 (February 10, 2011): 189–209. http://dx.doi.org/10.1146/annurev.pharmtox.010909.105851.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Cramer, Paula, and Michael Hallek. "New therapeutic targets and treatment strategies." Nature Reviews Clinical Oncology 9, no. 2 (January 10, 2012): 72–74. http://dx.doi.org/10.1038/nrclinonc.2011.212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Pryce Roberts, A., and N. P. Robertson. "Possible treatment targets in Alzheimer’s disease." Journal of Neurology 260, no. 12 (November 24, 2013): 3193–96. http://dx.doi.org/10.1007/s00415-013-7195-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Li, Jun-Xu, and Yanan Zhang. "Emerging drug targets for pain treatment." European Journal of Pharmacology 681, no. 1-3 (April 2012): 1–5. http://dx.doi.org/10.1016/j.ejphar.2012.01.017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Sellin, Joseph. "Treatment targets in inflammatory bowel disease." Advanced Drug Delivery Reviews 57, no. 2 (January 2005): 217–18. http://dx.doi.org/10.1016/j.addr.2004.08.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Pontius, Frederick W. "Surface Water Treatment Rule Targets Microbials." Opflow 19, no. 5 (May 1993): 7–8. http://dx.doi.org/10.1002/j.1551-8701.1993.tb01240.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Feng, Xun, and Yang Chen. "Drug delivery targets and systems for targeted treatment of rheumatoid arthritis." Journal of Drug Targeting 26, no. 10 (February 6, 2018): 845–57. http://dx.doi.org/10.1080/1061186x.2018.1433680.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

McGarrity, Sarah. "How 3,4,5-Trihydroxycinnamic Acid Targets Vascular Leakage: Potential Targeted Sepsis Treatment." Journal of Vascular Research 57, no. 5 (2020): 311–12. http://dx.doi.org/10.1159/000507629.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Srivastava, Shweta, Neha Shree Maurya, Shikha Kushwah, and Ashutosh Mani. "Current Promising Therapeutic Targets for Aspergillosis Treatment." Journal of Pure and Applied Microbiology 15, no. 2 (April 19, 2021): 484–99. http://dx.doi.org/10.22207/jpam.15.2.09.

Full text
Abstract:
Aspergillosis is a fungal disease caused by different species of Aspergillus. They live in soil,dust and decomposed material. Number of Aspergillus species found till now is about 300 and more are still to be identified. Only few Aspergillus species can cause human disease and the most common species for human infection is Aspergillus fumigatus, which is a ubiquitous airborne saprophytic fungus. Severity of the disease ranges from an allergic response to life-threatening generalized infection. They grow optimally at 37°C and can grow upto 50°C. The fungal conidia are being constantly inhaled by humans and animals everyday normally gets eliminated by innate immune mechanism. Due to increasing number of immunocompromised patients, severe and fatal Aspergillosis cases have augmented. Currently, available antifungal drug for the treatment of Aspergillosis act on these three molecular target are 14 alpha demethylase for Azoles, ergosterol for Polyene and β-1,3-glucan synthase for Echinocandin. These antifungal drug show high resistance problem and toxicity. So, it is high time to develop new drugs for treatment with reduced toxicity and drug resistant problem. Synthesis of essential amino acid is absent in human as they obtain it from their diet but fungi synthesis these amino acid. Thus, enzymes in this pathway acts as novel drug target. This article summarizes promising drug targets presents in different metabolic pathway of Aspergillus genome and discusses their molecular functions in detail. This review also list down the inhibitors of these novel target. We present a comprehensive review that will pave way for discovery and development of novel antifungals against these drug targets for Aspergillosis treatment.
APA, Harvard, Vancouver, ISO, and other styles
47

Petrovic, Nina, and Sercan Ergun. "miRNAs as Potential Treatment Targets and Treatment Options in Cancer." Molecular Diagnosis & Therapy 22, no. 2 (January 15, 2018): 157–68. http://dx.doi.org/10.1007/s40291-017-0314-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

von Haehling, Stephan, and Jochen Springer. "Treatment of Muscle Wasting: An Overview of Promising Treatment Targets." Journal of the American Medical Directors Association 16, no. 12 (December 2015): 1014–19. http://dx.doi.org/10.1016/j.jamda.2015.10.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Shao, Tingting, and Kai Huang. "Network Pharmacology-Based Analysis on Lonicera japonica for Chronic Osteomyelitis Treatment." Journal of Oncology 2022 (January 24, 2022): 1–10. http://dx.doi.org/10.1155/2022/1706716.

Full text
Abstract:
Ethnopharmacological Relevance. Lonicera japonica (LJP) is a broadly used traditional Chinese medication treatment for chronic osteomyelitis (COM). But, the main antiosteomyelitis compounds and functional targets of LJP are still unclear. Aim of the Study. To screen LJP drug targets and active compounds in COM treatment. Materials and Methods. Active compounds of LJP were examined established on the analysis platform, Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. DrugBank identified drug targets and annotated them on UniPort and GeneCards. Besides, the COM-related genes were identified on GeneCards. The network of the drug, main active compounds, targets, and diseases was built utilizing Cytoscape. STRING was utilized to build the protein-protein interaction network. Moreover, the KEGG and GO pathway enrichment analysis were applied to analyze biological function. Results. 23 active compounds of LJP were screened, and 204 drug targets and 686 COM-related genes were identified. Forty-five intersection genes were overlapped from 204 drug targets and 686 COM-related genes. The drug-active compounds-target protein-diseases network was established based on 23 active compounds of LJP and 45 intersection genes. Moreover, the interaction of 45 intersection genes was explored by the PPI network, and the drug-active compounds-target protein-diseases network was formed grounded by 23 active compounds of LJP, 45 intersection genes, and PPI network. The KEGG and GO pathway enrichment analysis specified that 45 intersection genes primarily enriched in immune-related pathways and oxidative stress-related pathways. Conclusions. In the research done, the main active compounds of LJP and drug targets in the treatment of COM were identified. Our findings might provide the ingredient option of LJP and drug targets of LJP in COM treatment.
APA, Harvard, Vancouver, ISO, and other styles
50

Reynolds, T. M. "Targeted lipid treatment: decades of failure suggest new targets are in order." International Journal of Clinical Practice 67, no. 12 (November 19, 2013): 1214–16. http://dx.doi.org/10.1111/ijcp.12240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Treatment targets' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography